Ocular screening for chronic graft-versus-host disease in patients with allogeneic hematopoietic stem cell transplant
Canadian Journal of Ophthalmology · 2025-02 · 60 (1) · e11-e15
DOI: 10.1016/j.jcjo.2024.04.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Journal of Ophthalmology, 2025-02. Verfasst von Bryan G Pearson und 3 weiteren Autor:innen. Beteiligte Einrichtung: John Sealy School of Medicine, University of Texas Medical Branch, Galveston, TX. Hauptthemen laut MEDLINE: Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Mass Screening, Dry Eye Syndromes. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: University of Texas Medical Branch.
Abstract (Originalsprache)
OBJECTIVE: This study investigates ocular manifestations of graft-versus-host disease in patients following allogeneic hematopoietic stem cell transplantation (HSCT) at the University of Texas Medical Branch (UTMB). Preferred practice pattern guidelines are proposed for ocular graft-versus-host disease (oGHVD) detection. METHODS: The Epic electronic medical record database at UTMB was screened using International Classification of Diseases, Tenth Revision (ICD-10), codes for bone marrow transplants, stem cell transplants, and complications of bone marrow transplants and stem cell transplants. We identified 50 patients with the ICD-10 codes that were seen at UTMB between 2000 and 2021. Patients who received an HSCT and follow-up care with UTMB were included in this study. Thirty-eight patients met the inclusion criteria, whereas 12 patients were excluded because they had no diagnosis of HSCT or did not follow-up with UTMB. RESULTS: Of the 38 patients in our cohort, 23.7% (n = 9) were noted to have oGVHD. As many as 89% of the patients with oGVHD presented with an ocular surface disease including keratoconjunctivitis sicca, meibomian gland dysfunction, and dry eye syndrome. Systemic GVHD also was found in 44% of the patients with oGVHD. Only 29% (n = 11) of the study population had referrals to ophthalmology. Most referrals (55%) were made within 1 year of getting the HSCT. None of the patients in our cohort received an ocular screening before HSCT. CONCLUSIONS: Many post-HSCT patients lack routine ophthalmic care. Regularly assessing post-HSCT patients for early signs and symptoms of oGVHD may limit adverse outcomes. Management of oGVHD should involve a multidisciplinary team approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- John Sealy School of Medicine, University of Texas Medical Branch, Galveston, TX.
- Department of Ophthalmology and Visual Sciences, University of Texas Medical Branch, Galveston, TX; Ophthalmology Associates of San Antonio, San Antonio, TX.
- Department of Ophthalmology and Visual Sciences, University of Texas Medical Branch, Galveston, TX. Electronic address: prgupta@utmb.edu.
Förderung
- University of Texas Medical Branch
Zitieren
APA
Pearson, B. G., Cortez, R. S., Khimani, K. S., & Gupta, P. K. (2025). Ocular screening for chronic graft-versus-host disease in patients with allogeneic hematopoietic stem cell transplant. Canadian Journal of Ophthalmology, 60(1), e11-e15. https://doi.org/10.1016/j.jcjo.2024.04.005
Vancouver
Pearson BG, Cortez RS, Khimani KS, Gupta PK. Ocular screening for chronic graft-versus-host disease in patients with allogeneic hematopoietic stem cell transplant. Canadian Journal of Ophthalmology. 2025;60(1):e11-e15. doi:10.1016/j.jcjo.2024.04.005
BibTeX
@article{Pearson2025,
author = {Pearson, Bryan G and Cortez, Ray S and Khimani, Karima S and Gupta, Praveena K},
title = {Ocular screening for chronic graft-versus-host disease in patients with allogeneic hematopoietic stem cell transplant},
journal = {Canadian Journal of Ophthalmology},
year = {2025},
volume = {60},
number = {1},
pages = {e11--e15},
doi = {10.1016/j.jcjo.2024.04.005}
}
EUVIMED